PD‐L1 expression enhancement by infiltrating macrophage‐derived tumor necrosis factor‐α leads to poor pancreatic cancer prognosis

Immunotherapy using anti‐PD‐1/PD‐L1 antibodies for several types of cancer has received considerable attention in recent decades. However, the molecular mechanism underlying PD‐L1 expression in pancreatic ductal adenocarcinoma (PDAC) cells has not been clearly elucidated. We investigated the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsukamoto, Masayo, Imai, Katsunori, Ishimoto, Takatsugu, Komohara, Yoshihiro, Yamashita, Yo‐ichi, Nakagawa, Shigeki, Umezaki, Naoki, Yamao, Takanobu, Kitano, Yuki, Miyata, Tatsunori, Arima, Kota, Okabe, Hirohisa, Baba, Yoshifumi, Chikamoto, Akira, Ishiko, Takatoshi, Hirota, Masahiko, Baba, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317925/
https://www.ncbi.nlm.nih.gov/pubmed/30426611
http://dx.doi.org/10.1111/cas.13874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317925/
https://www.ncbi.nlm.nih.gov/pubmed/30426611
http://dx.doi.org/10.1111/cas.13874

Ejemplares similares